MRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer.
Ontology highlight
ABSTRACT: Intrinsic and acquired resistance to the monoclonal antibody drug trastuzumab is a major problem in the treatment of HER2-positive breast cancer. A deeper understanding of the underlying mechanisms could help to develop new agents. Our intention was to detect genes and single nucleotide polymorphisms (SNPs) affecting trastuzumab efficiency in cell culture. Three HER2-positive breast cancer cell lines with different resistance phenotypes were analyzed. We chose BT474 as model of trastuzumab sensitivity, HCC1954 as model of intrinsic resistance, and BTR50, derived from BT474, as model of acquired resistance. Based on RNA-Seq data, we performed differential expression analyses on these cell lines with and without trastuzumab treatment. Differentially expressed genes between the resistant cell
SUBMITTER: von der Heyde S
PROVIDER: S-EPMC4339844 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
ACCESS DATA